Combining Troponin T and BNP Better Predicts Outcomes in Cardiac Sarcoidosis | Research

The takeaway

In cardiac sarcoidosis patients, elevated high-sensitivity troponin T combined with elevated BNP predicted a 3.5-fold higher risk of death, dangerous arrhythmias, or heart failure hospitalization.

3.49× risk
Patients with both elevated troponin T and elevated BNP at diagnosis had 3.49 times the risk of major cardiac events compared to those with both markers low.

What the researchers found

Patients with both high hs-cTnT (>0.016 ng/mL) and high BNP (>140 pg/mL) had a 3.49-fold increased risk of adverse cardiac events compared to those with both markers low.

Why it matters

Cardiac sarcoidosis is an unpredictable inflammatory condition that can cause sudden death. Having simple blood biomarkers — especially the combination of troponin and BNP — that identify higher-risk patients at diagnosis could guide decisions about more aggressive monitoring or treatment.

How the study worked

Post-hoc analysis of the ILLUMINATE-CS multicenter retrospective cohort (103 patients with cardiac sarcoidosis), using Cox regression analysis with median 2.6-year follow-up.

What this study cannot tell us

Retrospective design and small sample size (103 patients, 24 events) limit statistical power and generalizability. The study was conducted entirely in Japanese patients, which may not reflect other populations. Median cut-points for biomarker classification are somewhat arbitrary. The post-hoc analysis nature limits causal inference.

How to read the evidence

This is a post-hoc analysis of a retrospective multicenter cohort. The sample size is small and the analysis exploratory, which means these findings need prospective validation before clinical adoption.

When this study was published

Published in 2025, using data from the ILLUMINATE-CS registry — a dedicated cardiac sarcoidosis cohort, which is notable given how rare this condition is.

The bigger picture

BNP and troponin are the two most widely used cardiac biomarkers, but their combined prognostic value in cardiac sarcoidosis has been understudied. This finding reinforces that natriuretic peptide measurement adds meaningful prognostic information even in rare inflammatory heart conditions, not just the common heart failure settings where BNP is standard.

Questions still open

Should combined troponin-BNP measurement become standard at cardiac sarcoidosis diagnosis?
Could serial BNP monitoring guide immunosuppressive therapy intensity in cardiac sarcoidosis?
Do these biomarker thresholds apply to non-Japanese cardiac sarcoidosis populations?

Common questions

What is cardiac sarcoidosis?

Sarcoidosis is an inflammatory disease that can affect the heart, causing scarring that leads to arrhythmias, heart failure, or sudden death. It is relatively rare and difficult to predict who will have severe outcomes, making prognostic biomarkers particularly valuable.

Why measure both troponin and BNP together?

Troponin reflects active heart muscle damage while BNP indicates heart wall stress. Together, they capture two different aspects of cardiac injury. This study found their combination predicted outcomes better than either alone in cardiac sarcoidosis.

Read the original research

Prognostic role of high-sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE-CS.

ESC heart failure, 12(2), 869-878

View on PubMed ↗Publisher’s paper ↗

Citation

Baba, Yuichi; Kubo, Toru; Nabeta, Takeru; Matsue, Yuya; Kitai, Takeshi; Naruse, Yoshihisa; Taniguchi, Tatsunori; Tanaka, Hidekazu; Okumura, Takahiro; Yoshioka, Kenji; Kitaoka, Hiroaki. (2025). Prognostic role of high-sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE-CS.. ESC heart failure, 12(2), 869-878. https://doi.org/10.1002/ehf2.15058